Quadrature Capital’s Royalty Pharma RPRX Stock Holding History

Quadrature Capital’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,313	Closed	-$205K	–	1783
2025 Q4	$205K	Buy	+5,313	New	+$203K	﹤0.01%	966
2023 Q3	–	Sell	-24,133	Closed	-$742K	–	1229
2023 Q2	$742K	Buy	+24,133	New	+$817K	0.02%	481
2022 Q2	–	Sell	-7,298	Closed	-$284K	–	935
2022 Q1	$284K	Buy	+7,298	New	+$287K	0.01%	528
2021 Q3	–	Sell	-7,700	Closed	-$316K	–	987
2021 Q2	$316K	Buy	+7,700	New	+$328K	0.01%	648

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Quadrature Capital's RPRX Position: Q1 2026 in Review

Quadrature Capital sold out of Royalty Pharma (RPRX) in Q1 2026, closing a stake of 5,313 shares — an estimated $205K sold.

Quadrature Capital first reported a position in RPRX in Q2 2021 and held it in 4 quarters. The position peaked at $742K in Q2 2023. 592 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Quadrature Capital reported no remaining Royalty Pharma position as of Q1 2026 after selling out during the quarter.
Quadrature Capital sold 5,313 Royalty Pharma shares in Q1 2026, an estimated $205K.
Quadrature Capital first reported a position in Royalty Pharma in Q2 2021 and held it in 4 quarters.
Quadrature Capital's Royalty Pharma position peaked at $742K in Q2 2023.
592 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.